MAB3262F
Anti-BrdU Antibody, clone PRB-1, FITC conjugated
clone PRB-1, Chemicon®, from mouse
Synonyme(s) :
BrdU
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
A propos de cet article
UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Conjugate:
FITC conjugate
Clone:
PRB-1, monoclonal
Application:
FACS
Citations:
12
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderService technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderbiological source
mouse
conjugate
FITC conjugate
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
PRB-1, monoclonal
species reactivity (predicted by homology)
all
manufacturer/tradename
Chemicon®
technique(s)
flow cytometry: suitable
isotype
IgG1
shipped in
wet ice
target post-translational modification
unmodified
Quality Level
Catégories apparentées
Immunogen
Iodouridine conjugated to ovalbumin.
Application
Anti-BrdU Antibody, clone PRB-1, FITC conjugated is a Mouse Monoclonal Antibody for detection of Bromodeoxyuridine also known as BrdU & has been validated in FC.
Flow cytometry: 1:20
Optimal working dilutions must be determined by the end user.
Optimal working dilutions must be determined by the end user.
Research Category
Epigenetics & Nuclear Function
Epigenetics & Nuclear Function
Research Sub Category
Cell Cycle, DNA Replication & Repair
Cell Cycle, DNA Replication & Repair
Biochem/physiol Actions
Recognizes BrdU in ssDNA, free BrdU or BrdU coupled to a protein carrier. MAB3262 also reacts with iodouridine. Does not react with thymidine.
Physical form
Purified immunoglobulin conjugated to fluorescein. Liquid in PBS with 0.05% sodium azide pH 7.4
Preparation Note
Maintain at 2-8°C in undiluted aliquots up to 6 months. Protect from prolonged exposure to light.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Vous ne trouvez pas le bon produit ?
Essayez notre Outil de sélection de produits.
Classe de stockage
12 - Non Combustible Liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
CCN1 induces hepatic ductular reaction through integrin ?v??-mediated activation of NF-?B.
Kim, KH; Chen, CC; Alpini, G; Lau, LF
The Journal of Clinical Investigation null
Yan Fan et al.
Neurotoxicity research, 38(3), 793-807 (2020-07-04)
The present study investigated the effects of forced overexpression of Phox2a/2b, two transcription factors, in the locus coeruleus (LC) of aged rats on noradrenergic and dopaminergic phenotypes in brains. Results showed that a significant increase in Phox2a/2b mRNA levels in
Johana M Susanto et al.
International journal of oncology, 46(5), 2223-2230 (2015-02-20)
Despite incremental advances in the diagnosis and treatment for pancreatic cancer (PC), the 5‑year survival rate remains <5%. Novel therapies to increase survival and quality of life for PC patients are desperately needed. Epigenetic thera-peutic agents such as histone deacetylase
Songyu Li et al.
Cell death & disease, 11(4), 219-219 (2020-04-07)
DNA damage results in mutations and plays critical roles in cancer development, progression, and treatment. Targeting DNA damage response in cancers by inhibiting poly-(ADP-ribose) polymerases (PARPs) offers an important therapeutic strategy. However, the failure of PARP inhibitors to markedly benefit
Yu Yan et al.
Oncology reports, 51(2) (2023-12-15)
The radioresistance of glioma is an important cause of treatment failure and tumor aggressiveness. In the present study, under performed with linear accelerator, the effects of 0.3 and 3.0 Gy low‑dose radiation (LDR) on the proliferation and migration of C6 glioma
Contenu apparenté
Numéro d'article de commerce international
| Référence | GTIN |
|---|---|
| MAB3262F | 04053252577802 |
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique